Kinase Inhibitor Discovery

 

( キナーゼ阻害剤の創薬 )

The human kinome is a very large and druggable class of targets with many disease indications. Thus, the kinome targets account for a significant portion of drug discovery efforts. Kinase inhibitor discovery is a very active area as developers explore more deeply into designing immune-modulatory agents as single or combination therapies, tackling chronic disease indications such as inflammation and CNS disorders as well as effectively harnessing allosteric modulators and covalently binding compounds. This year we'll also be discussing PROTACs and the role of artificial intelligence in kinase inhibitor discovery.

RECOMMENDED PREMIUM PACKAGE:
Choose 2 Short Courses and 2 Conferences/Training Seminars
September 16 Pre-Conference Short Course: SC5: Applications of Artificial Intelligence and Machine Learning in Drug Discovery and Development
September 17-18 Conference: Emerging Ubiquitin and Autophagy Targets
September 18 Dinner Short Course: SC8: Targeted Protein Degradation Using PROTACs, Molecular Glues and More
September 18-19 TS3: Introduction to Small Molecule Drug Discovery and Development

Final Agenda

9月18日(水)

11:20 am Conference Registration Open


PLENARY KEYNOTE PROGRAM
Click here for full abstracts.

12:20 pm Event Chairperson’s Opening Remarks

An-Dinh Nguyen, Team Lead, Discovery on Target 2019, Cambridge Healthtech Institute

 

12:30 Plenary Keynote Introduction

Anjan Chakrabarti, Vice President, Discovery Chemistry, Syngene International Ltd

12:40 Base Editing: Chemistry on a Target Nucleotide in the Genome of Living Cells

David R. Liu, PhD, Howard Hughes Medical Institute Investigator, Professor of Chemistry & Chemical Biology, Harvard University

 

 

1:20 PROTACs: Past, Present, and Future

Craig M. Crews, PhD, Professor, Chemistry; Pharmacology; Molecular, Cellular & Developmental Biology; Yale University

 

 

2:00 Close of Plenary Keynote Program

2:00 Dessert Break in the Exhibit Hall with Poster Viewing

新たな課題と可能性

2:45 Organizer's Welcome Remarks

2:50 Chairperson’s Opening Remarks

Mary M. Mader, PhD, Vice President, Chemistry, Relay Therapeutics, Inc.

2:55 Targeting Human Pseudokinases with Kinase Inhibitors

Eyers_PatrickPatrick Eyers, PhD, Professor, Cell Signaling, Biochemistry, University of Liverpool

Protein pseudokinases are atypical (usually inactive) members of the human kinome. The thriving pseudokinase field is strongly placed to benefit from decades of research undertaken on canonical protein kinases, and the approval of ~50 kinase inhibitors in oncology and inflammatory indications. In this talk, I will focus on the serendipitous discovery of covalent modulators of Tribbles 2 (TRIB2) pseudokinase, which induces a conformation that drives TRIB2 degradation in human cells.

3:25 Brain Penetrant Kinase Chemotherapeutics: Learnings from CNS Discovery

Mader_MaryMary M. Mader, PhD, Vice President, Chemistry, Relay Therapeutics, Inc.

Brain penetrance is significantly impacted by the physicochemical properties of the drugs. Compound properties associated with brain penetrance have been analyzed recently for kinase inhibitors in glioblastoma trials, although many of these examples exploit opportunities identified in clinical development rather than specific compound design strategies. An examination of kinase inhibitors that were optimized specifically for CNS indications could provide insight into preferred property space and lead to greater success in neuro-oncology efforts.

3:55 Sponsored Presenation (Opportunity Available)

4:25 Refreshment Break in the Exhibit Hall with Poster Viewing

5:00 Discovery and Development of PI4KIIIβ Inhibitors with a Unique Immuno-Suppressive Phenotype Enabling the Prolongation of Allogeneic Organ Engraftment

Helen Horsley, Senior Principal Scientist, Medicinal Chemistry, UCB Pharma

The target of a novel series of immunosuppressive piperazine ureas is the lipid kinase PI4KIIIβ and a link between inhibition of PI4KIIIβ and suppression of immune responses in vitro and in vivo has emerged. Here we detail the identification of UCB9608 and discuss the binding mode and selectivity profile of this novel inhibitor, and the implications this may have on the observed tolerogenic phenotype.

5:30 Targeted Therapy in Patients with PIK3CA-Related Overgrowth Syndrome

Canaud_GuillaumeGuillaume Canaud, MD, PhD, Professor of Medicine, Hôpital Necker Enfants Malades, Paris

PIK3CA-related overgrowth syndromes (PROS) are genetic disorders that result from somatic gain-of-function mutations of the PIK3CA gene. PROS has no specific treatment. We created the first mouse model of PROS that recapitulates the human disease and demonstrated the efficacy of BYL719, PIK3CA inhibitor. On the basis of these results, we used BYL719 to treat 19 patients with PROS. The drug improved the disease symptoms in all patients and was not associated with any substantial side effects.

6:00 Artificial Intelligence in Kinase Inhibitor Discovery

enyedy_istvanIstvan J. Enyedy, PhD, Principal Scientist, Biogen

Machine learning in combination with automated inhibitor optimization and statistical analysis may be used to accelerate kinase inhibitor discovery. The performance of a prototype artificial intelligence protocol will be presented.

6:30 Dinner Short Course Registration
Click here for details on short courses offered.

9:30 Close of Day

9月19日(木)

7:00 am Registration Open

7:30 Interactive Breakfast Breakout Discussion Groups - View All Breakouts

Grab a cup of coffee and join a breakout discussion group. These are informal, moderated discussions with brainstorming and interactive problem solving, allowing participants from diverse backgrounds to exchange ideas and experiences and develop future collaborations around a focused topic.

What Are the Next Actionable Precision Oncology Approaches?

Moderator: Vijaya Tirunagaru, PhD, VP, Head of Biology and Non-Clinical Development, Research, Rain Therapeutics

  • Technologies to identify novel oncogenic drivers
  • Mapping of driver mutations to specific patient populations
  • Synthetic lethality approaches

Artificial Intelligence in Kinase Drug Discovery and Development

Moderator: Istvan J. Enyedy, PhD, Principal Scientist, Biogen

  • Use of AI in kinase inhibitor drug design and optimization
  • Pros and cons of AI in drug discovery
  • What is a novel kinase inhibitor and how can we expand the chemical space of kinase inhibitors?

8:30 Transition to Sessions

承認済みおよび臨床試験段階の先進的な阻害剤

8:40 Chairperson’s Remarks

Istvan J. Enyedy, PhD, Principal Scientist, Biogen

8:45 Characterization of HER2 Mutations Identified in a Patient with an Initial Response and Acquired Resistance to Neratinib

Hanker_AriellaAriella B. Hanker, PhD, Assistant Professor, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center

HER2 is mutated in 2-4% of breast cancers. We identified a HER2T798I gatekeeper mutation in a patient with HER2L869R-mutant breast cancer with acquired resistance to the HER2 TKI neratinib. Laboratory studies suggested that HER2L869R is a neratinib-sensitive, gain-of-function mutation. The patient exhibited a sustained partial response on neratinib. Upon progression, acquired HER2T798I was detected. Structural modeling and laboratory studies showed that HER2T798I prevented neratinib binding, which was overcome by afatinib.

9:15 Discovery of BLU-667 for RET-Driven Cancers

Brubaker_JasonJason Brubaker, PhD, Director of Chemistry, Blueprint Medicines

BLU-667 is an oral precision therapy designed for highly potent and selective targeting of oncogenic RET alterations and resistance mutants. Our fully annotated kinase inhibitor library was used to identify several RET inhibitor scaffolds. The optimization of these starting points to lead to the discovery of BLU-667 will be described.

9:45 Targeting PI3K-gamma with IPI-549, a Tumor Macrophage-Reprogramming Small Molecule, in Patients with Advanced Solid Tumors

Kutok_JefferyJeffery L. Kutok, MD, PhD, CSO, Infinity Pharmaceuticals, Inc.

IPI-549 is a first-in-class, oral, selective PI3K-γ inhibitor that in preclinical studies reprograms tumor macrophages from an immune-suppressive (M2) phenotype, to an immune-activating (M1) phenotype and can overcome intrinsic resistance to checkpoint inhibitors. A Ph 1/1b study IPI-549-01 (NCT02637531) is evaluating the safety, efficacy, tolerability, pharmacokinetics, pharmacodynamics, and immunomodulatory activity of IPI-549 as monotherapy and combined with nivolumab, in over 200 patients with advanced solid tumors.

10:15 Coffee Break in the Exhibit Hall with Poster Viewing and Poster Competition Winner Announced

10:55 Tarloxotinib, a Hypoxia Activated Prodrug for EGFR and HER2 Exon 20 Insertion Mutant NSCLC

Tirunagaru_VijayaVijaya Tirunagaru, PhD, VP, Head of Biology and Non-Clinical Development, Research, Rain Therapeutics

EGFR and HER2 exon 20 insertion mutations in non-small cell lung cancers are resistant to current EGFR inhibitors and lack effective therapy. The similarity of exon20 insertions to WT EGFR in the drug binding pocket limits the therapeutic window for WT EGFR mediated toxicities. Tarloxotininb selectively releases active EGFR inhibitor in the hypoxic tumors and enhances tumor dose intensity while minimizing systemic toxicities.

タンパク質分解の新たな手法と応用分野

11:25 Orally Active IRAK4 Degraders for Oncology and Autoimmune Diseases

Mainolfi_NelloNello Mainolfi, PhD, Founder and CSO, Kymera Therapeutics, Inc.

Targeted protein degradation combines the power of eliminating a disease-causing protein with the advantages of small molecule circulation in the body. Kymera is pioneering and advancing this technology by designing novel heterobifunctional molecules that engage the target protein and the E3 ligases to direct the target protein to be selectively degraded by the ubiquitin proteasome system. We have utilized this technology to successfully degrade IRAK4, a key node in innate immunity and cancer. This talk will describe the investigation of the pharmacology of IRAK4 degraders, in cellular systems and in vivo.

11:55 SELECTED POSTER PRESENTATION: Identifying New Drug Targets by Illuminating the Druggable Genome 

Karlie R. Sharma, PhD, Program Officer, National Center for Advancing Translational Sciences. National Institutes of Health

Existing clinical drugs only target a few hundred of the ~3,000 genes considered to be druggable, leaving a sizable subset of proteins within three druggable protein families (ion channels, GPCRs and kinases) that still remain largely understudied.  To address this, the National Institutes of Health (NIH) Common Fund has launched the Illuminating the Druggable Genome (IDG) Program, with the overall goal of catalyzing research to improve our understanding of the properties and functions of proteins that are currently not well studied within commonly drug-targeted protein families. 

12:25 pm Session Break

Eurofins Discovery 12:35 Luncheon Presentation: Use of InCELL Pulse™ Cellular Thermal Shift Target Engagement Assays in Early Drug Discovery

Shapiro_PaulPaul Shapiro, PhD, Group Leader, Assay and Product Development, Research and Development Department, Eurofins DiscoverX

A common problem in early target-based drug discovery is the lack of correlation between potencies, or even rank order of potencies, derived from initial biochemical screens and those observed in cellular assays. In phenotypic screening approaches, often the actual drug target is unknown and needs to be identified and proven. Cellular thermal shift assays for target engagement are of increasing interest because they bridge these gaps, however, existing technologies have been cumbersome and low-throughput. InCELL Pulse™, using Eurofins DiscoverX Enzyme Fragment Complementation technology, is a rapid, homogeneous, cell-based assay based on ligand-induced changes in protein thermal stability and is used to study drug-target engagement in live cells. We have successfully applied InCELL Pulse™ to rapidly measure quantitative cellular target engagement potency values for ligands of diverse intracellular protein classes such as kinases, methyltransferases, and hydrolases.  

1:25 Refreshment Break in the Exhibit Hall with Poster Viewing

タンパク質分解の新たな手法と応用分野 (続き)

2:05 Chairperson’s Remarks

Nello Mainolfi, PhD, Founder and CSO, Kymera Therapeutics, Inc.


2:10 KEYNOTE PRESENTATION AND DISCUSSION: Targeting Kinases for Degradation- Challenges and Opportunities

Gray_NathanaelNathanael S. Gray, PhD, Professor of Biological Chemistry and Molecular Pharmacology, Dana-Farber Cancer Institute

Heterobifunctional molecules that recruit E3 ubiquitin ligases, such as cereblon, for targeted protein degradation represent an emerging pharmacological strategy. A major unanswered question is how generally applicable this strategy is to all protein targets. In this talks I will discuss our efforts to develop chemoproteomic strategies to identify degradable kinases. Methods to characterize small molecule kinase degraders will also be discussed.

3:10 Novel Strategies for Oncoprotein Degradation

Willem den Besten, PhD, Senior Scientific Researcher, Genentech

Targeted protein degradation has the potential to open the door to therapeutic targets previously deemed undruggable. In this talk, I will present the characterization of two ligase ligands and show how target degradation coupled with modulation of ligase biology leads to increased cellular efficacy. I will also share results on a new method for inducing the degradation of an ubiquitin ligase.

3:40 E3 Ubiquitin Ligases for PROTACs Discovery

Matthieu Schapira, PhD, Principal Investigator, Structural Genomics Consortium and Associate Professor, Pharmacology & Toxicology, University of Toronto

To be active, a PROTAC must induce the formation of a productive complex between a target of interest and a structurally and functionally compatible E3 ubiquitin ligase. Considering that less than ten E3 ligases out of over 600 in the human proteome are exploited by current PROTACs, extending the repertoire of lig-ands to E3 ligases with a variety of structural properties as well as diverse temporal and spatial expression profiles should considerably expand potential applications of PROTACs for chemical biology, and broaden the horizon for future drug discovery efforts. I will review the classification, ubiquitin-proteasome system association, tissue expression profile and druggability of human E3 ligases.

4:10 Close of Conference

* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。

Choose your language
Traditional Chinese
Simplified Chinese
Korean
English


更新履歴
2019/09/06
イベント情報更新
2019/08/29
アジェンダ・スポンサー更新
2019/07/26
講演者・スポンサー更新
2019/07/09
スポンサー更新
2019/05/28
アジェンダ・スポンサー更新
2019/04/18
イベント情報更新



Premier Sponsors

AbCellera

Ablexis Alivamab_stacked

Charles-River

Eurofins

Integral

OmniAb Ligand_Pharmaceuticals

Synthego



メール配信サービス